Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022--…
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage…
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
- Advancing ARCUS® Platform by Developing In Vivo Gene Editing Programs for Genetic Diseases and Ex Vivo CAR T Therapies for Hematologic Malignancies - Presented Allogeneic CAR T Clinical Data at the…
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 8, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 4, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies…
Precision BioSciences Completes Spin-Out of Elo Life Systems
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies…
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
- Precision BioSciences is Simultaneously Advancing Development of PBCAR0191, as Potential First-in-Class, and PBCAR19B as Potential Best-in-Class CD19 Targeting Allogeneic CAR T Therapies - High…
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth , Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors - Hosted In Vivo Gene…